In vivo targeting of B-cell lymphoma with glycan ligands of CD22

Blood

Volumn 115, Issue 23, 2010, Pages 4778-4786

  Chen, Weihsu C ^a   Completo, Gladys C ^a   Sigal, Darren S ^b   Crocker, Paul R ^c   Saven, Alan ^b   Paulson, James C ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SCRIPPS CLINIC   (United States)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; CD22 ANTIGEN; DOXORUBICIN; GLYCAN; LIPOSOME; ANTINEOPLASTIC ANTIBIOTIC; CD22 PROTEIN, HUMAN; LIGAND; POLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BLOOD SAMPLING; CHO CELL; CHRONIC LYMPHATIC LEUKEMIA; DAUDI CELL; DRUG PROTEIN BINDING; ENDOCYTOSIS; FEMALE; HAIRY CELL LEUKEMIA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MARGINAL ZONE LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CRICETULUS; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG SCREENING; HAMSTER; IMMUNOLOGY; METHODOLOGY; MOUSE MUTANT; NONOBESE DIABETIC MOUSE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD22; CHO CELLS; CRICETINAE; CRICETULUS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; LIPOSOMES; LYMPHOMA, B-CELL; MICE; MICE, INBRED NOD; MICE, SCID; POLYSACCHARIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954729240     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-12-257386     Document Type: Article

References (49)

1. American Cancer Society: cancer facts and figures. American Cancer Society (www.cancer.org). 2008.
2. Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program. 2007;2007:233-242.
3. Castillo J, Winer E, Quesenberry P. Newer monoclonal antibodies for hematological malignancies. Exp Hematol. Jul. 2008;36(7):755-768.
4. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med. 2008;59:237-250. (Pubitemid 351291630)
5. Evans LS, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2003;362(9378):139- 146.
6. DiJoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia. 2007;21(11):2240-2245.
7. Haas KM, Sen S, Sanford IG, Miller AS, Poe JC, Tedder TF. CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. J Immunol. 2006;177(5):3063-3073. (Pubitemid 44277823)
8. Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang QC, FitzGerald DJ, Pastan I. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res. 2000;6(4):1476-1487. (Pubitemid 30226237)
9. DiJoseph JF, Dougher MM, Kalyandrug LB, et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res. 2006;12(1):242-249.
10. Du X, Beers R, Fitzgerald DJ, Pastan I. Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res. 2008;68(15):6300-6305.
11. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345(4):241-247. (Pubitemid 32695063)
12. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007;7(4):255-266.
13. Walker JA, Smith KG. CD22: an inhibitory enigma. Immunology. 2008;123(3):314-325.
14. Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009;86(3):215-223.
15. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145-160.
16. Shmeeda H, Mak L, Tzemach D, Astrahan P, Tarshish M, Gabizon A. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with upregulated folate receptors. Mol Cancer Ther. 2006;5(4):818-824.
17. Chang DK, Lin CT, Wu CH, Wu HC. A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PLoS One. 2009;4(1):e4171.
18. Cheng WW, Allen TM. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab′ fragments and single chain Fv. J Control Release. 2008;126(1):50-58.
19. Debbage P. Targeted drugs and nanomedicine: present and future. Curr Pharm Des. 2009;15(2):153-172.
20. Ikehara Y, Niwa T, Biao L, et al. A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res. 2006;66(17):8740-8748. (Pubitemid 44449191)
21. Ikehara Y, Shiuchi N, Kabata-Ikehara S, et al. Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells. Cancer Lett. 2008;260(1-2):137-145.
22. Bruehl RE, Dasgupta F, Katsumoto TR, et al. Polymerized liposome assemblies: bifunctional macromolecular selectin inhibitors mimicking physiological selectin ligands. Biochemistry. 2001;40(20):5964-5974.
23. Hashida N, Ohguro N, Yamazaki N, et al. High-efficacy site-directed drug delivery system using sialyl-Lewis X conjugated liposome. Exp Eye Res. 2008;86(1):138-149.
24. Zhang H, Ma Y, Sun XL. Recent developments in carbohydrate-decorated targeted drug/gene delivery. Med Res Rev. 2010:30(2)270-289.
25. Collins BE, Blixt O, Han S, et al. High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells. J Immunol. 2006;177(5):2994-3003. (Pubitemid 44277815)
26. O'Reilly MK, Collins BE, Han S, et al. Bifunctional CD22 ligands use multimeric immunoglobulins as protein scaffolds in assembly of immune complexes on B cells. J Am Chem Soc. 2008;130(24):7736-7745.
27. Green AE, Rose PG. Pegylated liposomal doxorubicin in ovarian cancer. Int J Nanomedicine. 2006;1(3):229-239.
28. Soloman R, Gabizon AA. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin. Clin Lymphoma Myeloma. 2008;8(1):21-32.
29. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophysica Acta. 1993;1151(2):201-215. [Erratum appears in Biochim Biophys Acta. 1994;1190(1):197.]
30. Tateno H, Li H, Schur MJ, et al. Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity. Mol Cell Biol. 2007;27(16):5699-5710. (Pubitemid 47257827)
31. Rempel H, Calosing C, Sun B, Pulliam L. Sialoadhesin expressed on IFN-induced monocytes binds HIV-1 and enhances infectivity. PLoS One. 2008;3(4):e1967.
32. van Rooijen N, van Kesteren-Hendrikx E. "In vivo" depletion of macrophages by liposomemediated "suicide." Methods Enzymol. 2003;373:3-16.
33. Ghetie MA, Tucker K, Richardson J, Uhr JW, Vitetta ES. Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail. Blood. 1994;84(3):702-707. (Pubitemid 24223863)
34. Newton DL, Hansen HJ, Mikulski SM, Goldenberg DM, Rybak SM. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood. 2001;97(2):528-535.
35. Blixt O, Han S, Liao L, et al. Sialoside analogue arrays for rapid identification of high affinity siglec ligands. J Am Chem Soc. 2008;130(21):6680-6681.
36. Zaccai NR, Maenaka K, Maenaka T, et al. Structure-guided design of sialic acid-based Siglec inhibitors and crystallographic analysis in complex with sialoadhesin. Structure. 2003;11(5):557-567.
37. Hartnell A, Steel J, Turley H, Jones M, Jackson DG, Crocker PR. Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations. Blood. 2001;97(1):288-296.
38. Oetke C, Vinson MC, Jones C, Crocker PR. Sialoadhesin-deficient mice exhibit subtle changes in B- and T-cell populations and reduced immunoglobulin M levels. Mol Cell Biol. 2006;26(4):1549-1557. (Pubitemid 43202578)
39. Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES. Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. Int J Cancer. 1990;45(3):481-485.
40. Robbins BA, Ellison DJ, Spinosa JC, et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood. 1993;82(4):1277-1287.
41. Sigal D, Saven A. Hairy cell leukemia. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds. Williams Hematology, Eighth Edition. New York, NY: McGraw-Hill; 2010.
42. Huang J, Fan G, Zhong Y, et al. Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B-cell chronic lymphoproliferative disorders from admixed benign B cells in four-color multiparameter flow cytometry. Am J Clin Pathol. 2005;123(6):826-832.
43. O'Reilly MK, Paulson JC. Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol Sci. 2009;30(5):240-248.
44. Collins BE, Paulson JC. Cell surface biology mediated by low affinity multivalent protein-glycan interactions. Curr Opin Chem Biol. 2004;8(6):617-625.
45. Gestwicki JE, Cairo CW, Strong LE, Oetjen KA, Kiessling LL. Influencing receptor-ligand binding mechanisms with multivalent ligand architecture. J Am Chem Soc. 2002;124(50):14922-14933.
46. Collins BE, Blixt O, DeSieno AR, Bovin N, Marth JD, Paulson JC. Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact. Proc Natl Acad Sci U S A. 2004;101(16):6104-6109. (Pubitemid 38520535)
47. Avilés A, Neri N, Castaneda C, Talavera A, Huerta-Guzman J, Gonzalez M. Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma. Med Oncol. 2002;19(1):55-58.
48. Levine AM, Tulpule A, Espina B, et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol. 2004;22(13):2662-2670.
49. Tsavaris N, Kosmas C, Vadiaka M, et al. Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma. Anticancer Res. 2002;22(3):1845-1848. (Pubitemid 34839207)